Urbanise.Com Limited

UBN

Urbanise.com Ltd designs and develops cloud-based Software as a Service (SaaS) platform for the property sector, specifically Strata and Facilities Management. The company is headquartered in North Sydney, New South Wales. The company went IPO on 2014-09-22. Its segments include Strata and Facilities. The company specializes in delivering cutting-edge proptech solutions through its two platforms: Urbanise Strata and Urbanise FM. The Strata platform manages the communications and accounting functions for apartment buildings, strata commercial towers and large housing communities. The Facilities Management platform manages the repair and maintenance for infrastructure, buildings, residential and commercial properties. Urbanise Strata serves strata managers in administering strata schemes and jointly owned properties. Urbanise FM software aids facilities managers in property asset maintenance and contractor supervision. Its client base spans across 17 countries with over 600,000 lots managed on Urbanise Strata and 2.2 million assets managed on Urbanise FM.

Uscom Limited

UCM

Uscom Ltd. engages in the development, design, manufacture, and marketing of non-invasive cardiovascular and pulmonary medical devices. The company is headquartered in Sydney, New South Wales. The company went IPO on 2003-12-10. The company specializes in the development and marketing of non-invasive cardiovascular and pulmonary medical devices. The company has three suites of devices in the field of cardiac, vascular, and pulmonary monitoring: the USCOM 1A advanced haemodynamic monitor, Uscom BP+ central blood pressure monitor, and the Uscom SpiroSonic digital ultrasonic spirometers. The USCOM 1A is a non-invasive advanced haemodynamic monitor that measures cardiovascular function, detects irregularities, and is used to guide treatment. The USCOM 1A device has applications in emergency, intensive care medicine and anesthesia. The Uscom BP+ is a supra-systolic oscillometric central blood pressure monitor which measures blood pressure and blood pressure waveforms in the heart, as well as in the arm, information only previously available using invasive cardiac catheterization. Its VENTITEST digital ultrasonic ventilator testing solution is a new system for testing ventilators.

Global X Us 100 ETF.

U100

U100.AX was created on 2023-08-21 by Global X. The fund's investment portfolio concentrates primarily on theme equity. The ETF currently has 45.44m in AUM and 100 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the Global X US 100 Index.

Universal Biosensors Inc.

UBI

Universal Biosensors, Inc. engages in the research, development and manufacture of medical diagnostics test systems for point-of-care professional and home use. The company is headquartered in Melbourne, Victoria. The company went IPO on 2006-12-13. The firm is engaged in developing and commercializing a range of biosensors in oenology (wine industry), human health including oncology, coagulation, women’s health and fertility, non-human and environmental testing using its platform technology and hand-held point-of-use devices. Its core technology consists of a disposable, multi-layer test strip, which incorporates an electrochemical sensing system using opposing electrodes that detect specific analytes in samples as small as a droplet. Its products include Sentia Wine Analyzer, Xprecia Prime Coagulation Analyzer, Hemostasis Reference Laboratory (HRL) and PETRACKR Veterinary Blood Glucose Monitoring System. HRL supports contract research organizations, central laboratories, early phase clinics, pharmaceutical/ biotechnology companies and academic researchers conducting clinical trials. HRL offers multiplex cytokine analysis on the MESO QuickPlex SQ 120MM technology platform.